

## Special Issue

# Pharmacotherapy of Thromboembolism

### Message from the Guest Editors

Thromboembolism is an emergency clinical situation with high mortality and postevent morbidity. The number of patients at risk for antithrombotic therapy-related complications who require long-term anticoagulation is increasing. Long-term therapy in patients with chronic diseases, elderly and frail patients, patients with cancer-related thromboembolism, or patients with the need for chronic anticoagulation who undergo vascular interventions could be problematic. This Special Issue has the aim to summarize the state-of-the-art drug discovery and drug design, and the latest findings in the field of long-term antithrombotic therapy, management of antithrombotic therapy in challenging clinical situations, and antithrombotic strategies in acute thrombotic complications during invasive vascular procedures.

---

### Guest Editors

Dr. Matej Samoř  
Dr. Tomáš Bolek  
Prof. Marián Mokáň

---

### Deadline for manuscript submissions

25 October 2026



## Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/149512](https://mdpi.com/si/149512)

*Pharmaceuticals*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)

[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





## Pharmaceuticals

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.8  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



## About the Journal

### Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

---

### Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)